Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research

Bacillus coagulans MTCC 5856 and Reduced Abdominal Pain

Research synthesisModerate evidenceLarge effect3 studies · 3 beneficial · 0 neutral · 0 harmful

Across all 3 studies, Bacillus coagulans MTCC 5856 consistently showed beneficial effects on reducing abdominal pain, with large effect sizes in 2 studies and a moderate effect in 1. The evidence, which includes a large systematic review (n=9253) and two smaller RCTs in clinical populations (IBS and functional gas/bloating), indicates benefit in adults with digestive complaints. Doses ranged from 2 billion spores/day to 2 × 10^9 CFU/day, though study durations were not consistently reported.

  • Effective dose range: 2 × 10^9 CFU/day (or 2 billion spores/day)
  • Studied populations: adults with IBS, adults with diarrhea-predominant IBS, adults with functional gas and bloating

Caveats: Available evidence is overwhelmingly positive — clinical literature in this area is subject to publication bias (null-result studies are less likely to be published or indexed). Evidence base is small (only 3 studies) — conclusions should be considered preliminary. Study durations were not reported for individual trials, limiting conclusions about time to effect.

Generated Jul 12, 2026
Doses used in studies
  • CFU/day: 2 billion (median 2 billion, IQR 2 billion2 billion) 1 study
  • spores/day: 2 billion (median 2 billion, IQR 2 billion2 billion) 1 study
Safety in these studies
3 of 3 papers
Back to top